Evolus (EOLS) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Evolus (EOLS) over the past year, gaining 66.2% versus a gain of 23.6%. Over five years, EOLS leads with a +0.9% price change compared with -62.3% for TKNO. Evolus is the larger company by market cap ($515.2 million vs $453.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | TKNO |
|---|---|---|
| Share price | $7.80 | $8.44 |
| Market cap | $515.19M | $453.13M |
| 1-day change | +0.78% | -3.10% |
| YTD return | +16.39% | +129.21% |
| 1-year return | +23.64% | +66.22% |
| 5-year return | +0.91% | -62.29% |
| Forward P/E | 26.67 | — |
| EPS (TTM) | $-0.53 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $9.48 |
| 52-week low | $3.86 | $1.91 |
| Distance from 52-week high | -16.22% | -10.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.31% | +6.64% |
| Average volume | 896.67K | 230.99K |
| Shares outstanding | 66.05M | 53.69M |
| Employees | 353 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TKNO has outperformed EOLS by 42.6 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
EOLS vs TKNO FAQ
Which is bigger, Evolus or Alpha Teknova?
Evolus (EOLS) is larger, with a market capitalization of $515.19M compared with $453.13M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, EOLS or TKNO?
TKNO returned +66.22% over the past 12 months, compared with +23.64% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Alpha Teknova in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Evolus and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Alpha Teknova.